Vicore Pharma Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Vicore Pharma Holding şirketinin toplam hissedar öz sermayesi SEK377.7M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK406.9M ve SEK29.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 380.42m
Eşitlik	SEK 377.74m
Toplam yükümlülükler	SEK 29.17m
Toplam varlıklar	SEK 406.90m

Son finansal sağlık güncellemeleri

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Sep 11

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26

Recent updates

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Sep 11

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Jan 10

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Mar 03

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

Jan 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VICO 'nin kısa vadeli varlıkları ( SEK406.9M ) kısa vadeli yükümlülüklerini ( SEK28.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: VICO şirketinin kısa vadeli varlıkları ( SEK406.9M ) uzun vadeli yükümlülüklerini ( SEK646.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VICO borçsuzdur.

Borcun Azaltılması: VICO un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VICO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: VICO serbest nakit akışı her yıl % 22.2 1.1 yıl yetecek nakit akışına sahip olacaktır.

Vicore Pharma Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Recent updates

Price target decreased by 7.6% to kr33.25

Vicore Pharma Holding AB (publ) to Report Q2, 2025 Results on Aug 22, 2025

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

New major risk - Shareholder dilution

Vicore Pharma Holding AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 782.138028 million.

We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate

Vicore Pharma Holding AB Initiates the Global, Randomized Phase 2B Aspre Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

Consensus revenue estimates increase by 100%

Consensus revenue estimates increase by 100%

Consensus revenue estimates increase by 100%

New minor risk - Share price stability

Less than half of directors are independent

Consensus EPS estimates fall by 20%

Vicore Pharma Holding AB (Publ) Announces Board Appointments

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Price target decreased by 13% to kr61.50

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

Consensus revenue estimates increase by 3,123,023%

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Price target decreased to kr74.67

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Now 20% undervalued after recent price drop

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Consensus forecasts updated

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Consensus forecasts updated

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Price target decreased to kr80.40

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Independent Director recently bought kr87k worth of stock

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Price target increased to kr93.50

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Price target decreased to kr55.00

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Price target increased to kr72.00

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.